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A B S T R A C T
In Croatia, there are about 355 incident cases and about 100 deaths from cervical cancer every year. The aim of this
study is to present the trends of cervical cancer incidence and mortality and to propose preventive strategies for cervical
cancer in Croatia. Age-standardised and age-specific cervical cancer incidence rates were calculated for the period
1985–2004. For cervical cancer mortality data, the WHO Mortality Database was used. After an early decrease of cervical
cancer incidence and mortality following the introduction of opportunistic screening in Croatia, no further decrease has
been observed since the 1990s. An increase in incidence over the last 20 years was observed in the age-groups 40–44 and
45–49 years. To reduce cervical cancer rates, an organised cervical cancer screening programme is essential. In addition,
HPV vaccination should be introduced in the school vaccination programme to achieve further reductions in cervical
cancer incidence in the future.
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Introduction
Cervical cancer is the second most common female
cancer worldwide with about 493,000 incident cases per
year, and it is the most common female cancer in Africa,
South America and Asia1. There are about 273,000 cervi-
cal cancer deaths in the world yearly, 85% of which take
place in developing countries1. In Europe, there are
about 50,000 new cases, and about 25,000 deaths yearly2.
The majority of incident cases occur between ages 30 and
50. The highest incidence of cervical cancer in Europe is
observed in Eastern European countries. As a conse-
quence of cervical cancer screening by Papanicolaou (Pap)
smear, cervical cancer incidence and mortality rates have
been decreasing over the last three decades in most of the
European countries. In countries with organised cervical
cancer screening programmes, cervical cancer is usually
the 10th most common female cancer1–3.
The Croatian population as assessed by the 2001 cen-
sus was 4.4 million4. The annual cancer incidence is
about 20,000 cases and cervical cancer is the 8th most
common female cancer in this country. There are on av-
erage 355 new cases, and about 100 deaths each year5,6.
Croatia has a lower cervical cancer incidence than most
Central and Eastern European countries, but it is still
much higher than in countries with organised cervical
cancer screening programmes1. Relative 5-year survival
of cervical cancer patients in Croatia diagnosed in the pe-
riod 1994–1998 was 74%7.
A possibility for primary prevention of cervical cancer
is vaccination against the Human papillomavirus (HPV)
that has been identified as a necessary cause of cervical
cancer8. About 60% of cervical cancer cases are attrib-
uted to HPV type 16, and additional 10–20% to HPV type
18 infection9–12. The currently available HPV vaccines
that have recently been approved in the US and Europe,
protect against the oncogenic HPV 16 and HPV 18 (qu-
adrivalent HPV types 6, 11, 16, 18 recombinant vaccine
GARDASIL®, Merck and Co.). Because the genital types
of HPV are primarily transmitted by sexual contact, the
optimal age for vaccination of girls is before the onset of
sexual activity. Vaccination of males has not been consid-
ered cost-effective13–15. The report on GARDASIL® effi-
ciency provided to the US Food and Drug Administration
and the European Medicines Agency, states that the vac-
cine can reduce HPV 16 or 18 related cervical intra-
epithelial neoplasia grade 2 and 3 (CIN 2/3) or adeno-
carsinoma in situ (AIS) by 39.0% (95% CI: 23.3–51.7),
while reducing treatment rates for any CIN by 16.5%
(95% CI 2.9–28.2)13,14.
37









 $  
The current HPV vaccines will not prevent all onco-
genic HPV infections and therefore cannot replace the
traditional cervical cancer screening. However, screening
methods and intervals may be modified to account for
changes in population risk for the development of this
disease15–18.
Historically, cervical cancer screening by Pap smear,
when followed by adequate therapy, has been proven to
substantially reduce cervical cancer incidence and mor-
tality. Following the introduction of such effective prog-
rammes, cervical cancer incidence and mortality has
been reduced by more than 80% particularly in British
Columbia and the Nordic countries19. The Pap smear was
introduced in the mid 1940s, and entered wider use in
the late 1950s. Organised national cancer screening prog-
rammes are currently available only in 8 EU countries
(Finland, Denmark, Iceland, Italy, Norway, Sweden, Slo-
venia and UK). The European guidelines specify that
cervical cancer screening programmes should target the
age-group 25–64 years20–22. The International Agency for
Research on Cancer (IARC) also recommends the intro-
duction of HPV-DNA screening within organised prog-
rammes in such a way that the efficacy and effectiveness
can be evaluated9.
Croatia does not have an organised national cervical
screening programme. Following the recommendations
for cervical cancer screening in Europe, a Working Group
of the Croatian Ministry of Health and Welfare has pro-
posed a national cervical cancer screening programme,
although this has not yet been introduced23. The pro-
posed programme comprises screening of women aged
25–64 years every three years by Pap smear in the first
phase. In the second phase of the programme, in addition
to Pap smear, HPV test would be introduced for women
aged 30–64, with five-year screening intervals23.
The aim of this study was to present the trends of cer-
vical cancer incidence and mortality between 1985 and
2004 in Croatia, and to propose preventive strategies for
cervical cancer in Croatia.
Materials and Methods
The source of data on cervical cancer mortality in
Croatia for the period 1985–2004 was the WHO mortal-
ity database24. Only the data for cervical cancer (ICD-10
code C53), without data on death associated to »Uterus
not otherwise specified« (NOS) (ICD-10 code C55) are
presented. However, the data on cervical cancer deaths
are likely to be underestimates since there are over one
hundred deaths per year from cancer of uterus NOS in
Croatia and a proportion of these will be due to cervical
cancer as well. For the data on cervical cancer incidence,
we used the Croatian National Cancer Registry data5. To
calculate the age-specific rates for the year 1985, we used
the Croatian population census for 1981; for the period
1986–1995 we used the Croatian population census for
1991; and for the period 1996–2004, we used the Cro-
atian population census for 20014,25,26. Age-standardised
rates of cancer incidence in Croatia for the period 1985–
2004 were calculated by the direct standardization method,
using the World standard population as a reference27.
Results
The age-standardised cervical cancer incidence rates
show a decreasing trend until the year 1991 but no fur-
ther consistent decrease in cervical cancer incidence has
been observed afterwards. The age-standardised rates of
cervical cancer mortality remained at a low level during
the entire period but no decrease was observed over the
last decade (Figure 1).
Table 1 shows the age-specific rates of cervical cancer
in Croatia for the age-groups targeted by the proposed
screening programme23. In the age groups between 25–
39 years, a decreasing trend of cervical cancer incidence
is observed. An increase of cervical cancer incidence over
the last 20 years has been observed in the age-groups
40–44 and 45–49 years. In the age groups between 50 and
64 years, a decrease of cervical cancer incidence is ob-
served, which is most prominent in the age group 60–64,
being over 5-fold over the 20-year period.
Discussion
Opportunistic cervical cancer screening was intro-
duced in Croatia in the 1960s and this was accompanied
by decreasing cervical cancer incidence and mortality
trends through to 1991. However, no substantial further
decreases in cervical cancer incidence and mortality were
observed subsequently (Figure 1). The largest decrease
of cervical cancer incidence over time is observed in
women between 25 and 39 years of age (Table 1). In addi-
tion to a higher awareness of the importance of preven-
tive medical examinations in these women, this could be
accounted for by opportunistic screening in scope of
gynecological examinations for either pregnancy or con-
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Fig. 1. World age-standardised rates (ASRW per 100,000 women-
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traceptive use counselling. However, the lack of a de-
creasing trend in women between 40 and 49 years of age
is more worrying, since this age-group comprises over a
quarter of the incident cervical cancer cases in Croatia
(Table 1). Meanwhile, the decrease of incidence in age-
-groups 50–64 probably reflects higher awareness of post-
menopausal women about the importance of gyneco-
logical examinations (Table 1).
The available evidence indicates that opportunistic
cervical cancer screening in Croatia has had an impact.
The number of Pap smears taken yearly is still increas-
ing and reached 433,671 in 2005. However, in the ab-
sence of an organised population-based programme it is
difficult to assess the efficacy of this screening and it is
clear that a large proportion of target population still re-
mains un-screened or under-screened23.
In spite of the decrease of cervical cancer incidence
following its introduction, opportunistic screening is not
an optimal method for the prevention of this disease as it
tends to overscreen the wealthy and well-educated while
under-screening the less affluent and minorities, thereby
creating inequalities in the healthcare that is delivered
to the population20. The only way to resolve this problem
and to achieve further reductions in cervical cancer cases
is through the introduction of an organised cervical can-
cer screening programme. Following the introduction of
such programmes, cervical cancer incidence and mortal-
ity has been reduced by more than 80% particularly in
British Columbia and the Nordic countries (Finland,
Denmark, Iceland, Norway and Sweden)19. In addition,
organised screening programmes are the only way that
countries will be able to derive the maximum benefit
from the new HPV vaccines that will soon be launched in
Croatia.
Conclusion
There is now a very urgent need to move forward with
the introduction of a comprehensive organised cervical
cancer prevention programme in Croatia. Indeed, this is
the only way that we will be able to further reduce cervi-
cal cancer rates while providing equitable, cost-effective
protection to all the women of Croatia.
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TABLE 1
AGE-SPECIFIC INCIDENCE RATES (PER 100,000 WOMAN-YEARS) OF CERVICAL CANCER IN CROATIA IN THE PERIOD 1985–2004
Year
Age-group
25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64
1985 9.4 22.6 38.7 17.7 20.7 28.7 39.1 66.1
1986 10.6 14.4 17.5 22.5 36.8 31.7 36.4 40.0
1987 10.0 15.0 19.1 17.8 29.1 24.6 32.1 36.7
1988 7.1 18.8 14.2 17.8 16.9 31.7 25.9 35.4
1989 15.3 15.5 20.2 18.4 23.0 24.6 31.4 42.0
1990 10.6 13.8 24.6 26.7 16.1 16.8 25.3 26.9
1991 5.9 18.3 20.2 18.4 26.1 16.2 18.5 30.2
1992 5.3 14.4 17.5 27.2 23.8 17.5 25.3 28.2
1993 11.8 17.7 38.8 26.7 19.9 25.3 21.0 23.0
1994 9.4 17.7 27.3 26.7 29.1 22.0 20.3 31.5
1995 7.1 15.5 26.2 34.9 30.7 22.7 26.5 26.2
1996 6.2 10.9 21.4 32.4 24.2 20.5 30.6 24.8
1997 9.6 13.6 30.9 30.0 24.2 19.8 19.0 21.2
1998 6.2 11.5 20.2 28.2 25.4 19.1 25.6 25.5
1999 6.9 20.3 21.4 25.2 21.8 23.8 32.2 33.3
2000 11.0 21.7 29.0 29.4 39.9 23.8 22.3 23.3
2001 7.5 12.9 30.9 28.2 21.8 18.5 13.2 21.9
2002 4.8 16.9 25.8 26.4 23.0 29.0 16.5 24.1
2003 4.8 10.8 18.3 24.6 25.4 19.8 23.9 18.4
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RAK VRATA MATERNICE U HRVATSKOJ: POSTOJE]E STANJE I MOGU]NOSTI ZA PREVENCIJU
S A @ E T A K
U Hrvatskoj godi{nje oko 355 `ena obolijeva, a oko 100 umire od raka vrata maternice. Cilj ovog rada bio je prikazati
trendove incidencije i mortaliteta od raka vrata maternice u Hrvatskoj te predlo`iti strategije za prevenciju. Izra~unate
su dobno-standardizirane i dobno-specifi~ne stope incidencije raka vrata maternice za razdoblje 1985–2004. Za podatke
o mortalitetu od raka vrata maternice koristili smo bazu podataka Svjetske zdravstvene organizacije. Nakon ranog
pada incidencije i mortaliteta od raka vrata maternice u Hrvatskoj koji je pratio uvo|enje oportunisti~kog probira,
daljnji pad se ne primje}uje nakon 1990-ih godina. Opa`en je porast incidencije u zadnjih 20 godina u dobnim sku-
pinama 40–44 i 45–49 godina. Da bi se smanjile stope incidencije i sprije~ile smrti od raka vrata maternice, potrebano je
{to prije uvo|enje organiziranog programa probira. Da bi se postiglo daljnje smanjenje incidencije raka vrata maternice,
potrebno je tako|er uvo|enje cjepiva protiv humanog papilomavirusa (HPV) u program obaveznog cijepljenja {kolske
djece.
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